Taken together, our findings emphasise the critical importance of assessing the cellular effects of prolonged exposure to investigational CF drugs in pre-clinical studies and provide compelling evidence for the potential benefit of including HGF in CF combination therapies, alerting the scientific community to the need and relevance of further in vivo studies with this physiological factor in the context of CF. The gene discussed is HGF; the disease is cystic fibrosis.